RAPGEF3 and cystic fibrosis: To test whether the effects of KH7 were mediated through EPAC1 as we have shown in CF cells, we treated cells with the EPAC1 selective activator 8-cpt-2-O-Me-cAMP (8-cpt-cA) to see if that would overcome the effects of sAC inhibition.